Wordt geladen...
The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
Gefitinib is an essential drug for NSCLC patients harboring EGFR sensitive mutations. The approved dose 250mg/day is based on limited clinical trials, this research aims to explore the relationship between drug exposure and gefitinib response. C(trough) of 87 NSCLC patients harboring EGFR sensitive...
Bewaard in:
| Gepubliceerd in: | Sci Rep |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4521154/ https://ncbi.nlm.nih.gov/pubmed/26228025 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep12675 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|